UFP Technologies (UFPT) Q1 2025 earnings summary

Executive summary

• Achieved record Q1 results with net sales up 41.1% to $148.1 million, net income up to $17.2 million, and EPS up 35% to $2.21 year-over-year, driven by 50.4% growth in the medical/MedTech segment and recent acquisitions.

• Major 2024 acquisitions contributed $40.7 million in Q1 sales, expanding capabilities and geographic reach.

• Safe Patient Handling became the second largest segment, with exclusive manufacturing agreements through 2030.

• Two largest customers accounted for 24.0% and 21.4% of Q1 net sales, highlighting customer concentration.

• Advanced Components/other markets declined 15% as focus shifted to MedTech opportunities.

Financial highlights

• Sales increased 41.1% to $148.1 million; medical market sales up 50.4% to $135.4 million; non-medical sales declined to $12.7 million.

• Gross margin slightly decreased to 28.5% from 28.6% year-over-year.

• Operating income rose to $23.1 million from $15.9 million; adjusted operating income up 49.5% to $25.8 million; adjusted EBITDA up 45.9% to $30.2 million.

• SG&A expenses rose 34.6% to $18.7 million, but as a percentage of sales decreased to 12.6%.

• GAAP and adjusted diluted EPS increased to $2.21 and $2.47, respectively; adjusted net income up 40.1% to $19.2 million.

Outlook and guidance

• Robotic Surgery segment expected to see only modest growth in 2025 after inventory build in 2024, with new programs launching in H2 2025 and meaningful revenue expected in 2026.

• Management expects continued inefficiency at newly acquired AJR operations through Q2 as onboarding continues.

• No material impact from tariffs anticipated; most tariff costs expected to be passed on.

• Normalized tax rate for 2025 projected at 21%-23%; effective tax rate was 15.3% in Q1.

• Existing resources and revolving credit facility are sufficient to fund requirements for the next twelve months.